LON:ONC

Oncimmune Share Forecast, Price & News

GBX 204.61

-2.39 (-1.15 %)

(As of 03/5/2021 09:49 AM ET)

Add

Compare

Today's Range

204

Now: GBX 204.61▼

210

50-Day Range

164.50

MA: GBX 186.20▼

221.50

52-Week Range

38.50

Now: GBX 204.61▼

222

Volume164,845 shs

Average Volume79,615 shs

Market Capitalization£130.36 million

P/E RatioN/A

Dividend YieldN/A

BetaN/A

Oncimmune Holdings plc develops and commercializes technologies that enable cancer diagnosis in the United Kingdom, North America, Europe, and internationally. It offers EarlyCDT-Lung, a blood test for early detection of lung cancer. The company also develops SeroTag, a platform that is used to discover and validate biomarkers that can help stratify patients in multiple cancer indications, infectious diseases, and with various autoimmune diseases; and NavigAID disease-specific stratification panels. Oncimmune Holdings plc was incorporated in 2015 and is based in Nottingham, the United Kingdom.

Headlines

Oncimmune loss narrows on revenue boost
February 15, 2021 | marketwatch.com

Oncimmune Interim Loss Narrows On Higher Revenue And Lower Costs
February 15, 2021 | lse.co.uk

DIRECTOR DEALINGS: Oncimmune Non-Exec Cheung To Sells 195,000 Shares
January 14, 2021 | lse.co.uk

Oncimmune Holdings PLC
November 14, 2020 | barrons.com

UK TRADING UPDATE SUMMARY: Mereo To Delist From AIM Amid Nasdaq Focus
November 13, 2020 | lse.co.uk

Oncimmune Holdings PLC (OCMMF)
August 17, 2020 | nasdaq.com

SMALL CAP SHARE IDEAS: Oncimmune highlights the resurgence of Britain's biotech sector during the pandemic
July 8, 2020 | www.msn.com

As Oncimmune Holdings hits a yearly high, is it too late to buy shares?
July 2, 2020 | uk.finance.yahoo.com

Oncimmune Holdings share price hits a new 52 week high
June 16, 2020 | uk.finance.yahoo.com

BRIEF-Oncimmune Holdings Announces Revenue In Line With Market Expectations For FY 2020
June 4, 2020 | www.reuters.com

Oncimmune Holdings hits 52w high – but will it continue?
June 1, 2020 | uk.finance.yahoo.com

Oncimmune Signs Drug Development Deal With US Biopharmaceutical Firm
May 15, 2020 | www.lse.co.uk

BRIEF-Oncimmune Signs Antigen Targeting Collaboration To Support Drug Development
May 12, 2020 | www.reuters.com

BRIEF-Oncimmune Announces Commercial Launch In U.S.
March 4, 2020 | www.reuters.com

Oncimmune EarlyCDT Lung Test Launched In US By Commercial Partner
March 4, 2020 | www.lse.co.uk

Oncimmune Half-Year Loss Widens As Business "Reshaping" Ups Expenses
February 12, 2020 | www.lse.co.uk

BRIEF-Oncimmune Holdings Says Revenue For HY Was £0.31 Mln
February 12, 2020 | www.reuters.com

Oncimmune Reports Study Results For Cancer Test Product
January 28, 2020 | www.lse.co.uk

Consortium of Liver Cancer Industry Leaders
January 23, 2020 | www.lse.co.uk

What Kind Of Shareholders Own Oncimmune Holdings Plc (LON:ONC)?
November 15, 2019 | finance.yahoo.com

See More Headlines

Industry, Sector and Symbol

Stock Exchange LON

Industry Diagnostics & Research

Sub-IndustryN/A

SectorMedical

Current SymbolLON:ONC

Previous Symbol

CUSIPN/A

CIKN/A

Weboncimmune.com

Phone+44-115-8231869

Employees72

Year FoundedN/A

Debt

Debt-to-Equity Ratio375.32

Current Ratio1.89

Quick Ratio1.79

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales£2.03 million

Price / Sales64.28

Cash FlowGBX 5.02 per share

Price / Cash Flow40.77

Book ValueGBX (3.80) per share

Price / Book-53.85

Profitability

EPS (Most Recent Fiscal Year)N/A

Net IncomeN/A

Net MarginsN/A

Return on EquityN/A

Return on AssetsN/A

Miscellaneous

Outstanding Shares63,710,000

Market Cap£130.36 million

Next Earnings DateN/A

OptionableNot Optionable

MarketRank^™

Overall MarketRank^™

0.42 out of 5 stars

0.0 Analyst's Opinion

Consensus Rating
There is not enough analysis data for Oncimmune.

2.1 Community Rank

Outperform Votes
Oncimmune has received 68 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Oncimmune has received 95 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Oncimmune has received 58.28% “underperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Oncimmune and other stocks. Vote “Outperform” if you believe ONC will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ONC will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Oncimmune does not currently pay a dividend.
Dividend Growth
Oncimmune does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Oncimmune insiders have sold 1,705.10% more of their company's stock than they have bought. Specifically, they have bought £9,971.72 in company stock and sold £180,000 in company stock.

0.0 Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of Oncimmune is -22.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Oncimmune is -22.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

See Top Rated MarketRank™ Stocks Here

GBX 204.61

-2.39 (-1.15 %)

(As of 03/5/2021 09:49 AM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive ONC News and Ratings via Email

Sign-up to receive the latest news and ratings for ONC and its competitors with MarketBeat's FREE daily newsletter.

Oncimmune (LON:ONC) Frequently Asked Questions

What stocks does MarketBeat like better than Oncimmune?

Wall Street analysts have given Oncimmune a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Oncimmune wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

How were Oncimmune's earnings last quarter?

Oncimmune Holdings plc (LON:ONC) announced its quarterly earnings results on Tuesday, February, 13th. The company reported ($5.70) earnings per share for the quarter. The business earned $0.08 million during the quarter.
View Oncimmune's earnings history.

How has Oncimmune's stock price been impacted by Coronavirus?

Oncimmune's stock was trading at GBX 70.50 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, ONC stock has increased by 190.2% and is now trading at GBX 204.61.
View which stocks have been most impacted by COVID-19.

Who are Oncimmune's key executives?

Oncimmune's management team includes the following people:

Dr. Adam Mark Hill Ph.D., CEO & Director (Age 41, Pay $385k)
Mr. Matthew Hall, Chief Financial Officer
Prof. Tariq Sethi M.D., B.Sc., M.A., Ph.D., FRCP, Chief Scientific Officer
Mr. Ron Kirschner, Gen. Counsel & Company Sec.
Dr. James R. Jett M.D., Chief Medical Officer of US
Mr. Maarten Brusse, Chief Commercial Officer of Asia
Mr. Shane Smith, Sr. VP of Market Access & Reimbursement Oncimmune (Usa)
Mr. Matthew Luttrell, Chief Commercial Officer
Mr. Andrew Millet BA, FCA, MBA, Exec. (Age 54)

Who are some of Oncimmune's key competitors?

Some companies that are related to Oncimmune include Biodesix (BDSX), Lucira Health (LHDX), Akumin (AKU), Akumin (AKU), Yourgene Health (YGEN), LexaGene (LXG), genedrive (GDR), Relay Medical (RYMDF), Global WholeHealth Partners (GWHP), SQI Diagnostics (SQD), Sernova (SVA), GeneNews (GEN), Cambridge Cognition (COG), Deepmatter Group (DMTR) and LED Medical Diagnostics (LMD).
View all of ONC's competitors.

What other stocks do shareholders of Oncimmune own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Oncimmune investors own include Actinium Pharmaceuticals (ATNM), Digi International (DGII), SeaChange International (SEAC), SMTC (SMTX), (APHA), (AQB), Axsome Therapeutics (AXSM), (BGSF), Chimerix (CMRX) and Constellation Pharmaceuticals (CNST).

What is Oncimmune's stock symbol?

Oncimmune trades on the London Stock Exchange (LON) under the ticker symbol "ONC."

How do I buy shares of Oncimmune?

Shares of ONC and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What is Oncimmune's stock price today?

One share of ONC stock can currently be purchased for approximately GBX 204.61.

How much money does Oncimmune make?

Oncimmune has a market capitalization of £130.36 million and generates £2.03 million in revenue each year.

How many employees does Oncimmune have?

Oncimmune employs 72 workers across the globe.

What is Oncimmune's official website?

The official website for Oncimmune is oncimmune.com.

Where are Oncimmune's headquarters?

Oncimmune is headquartered at Hucknall Road, NOTTINGHAM, NG5 1PB, United Kingdom.

How can I contact Oncimmune?

Oncimmune's mailing address is Hucknall Road, NOTTINGHAM, NG5 1PB, United Kingdom. The company can be reached via phone at +44-115-8231869.

This page was last updated on 3/6/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here